In this article:
Blurbs

BTIG Believes Accuray (ARAY) Still Has Room to Grow

In this article:
In this article:

BTIG analyst Marie Thibault reiterated a Buy rating on Accuray (ARAYResearch Report) today and set a price target of $9.00. The company’s shares closed last Wednesday at $5.52, close to its 52-week high of $6.02.

According to TipRanks.com, Thibault is a 5-star analyst with an average return of 43.8% and a 59.7% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Edwards Lifesciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Accuray with a $8.50 average price target, implying a 57.7% upside from current levels. In a report issued on October 26, Lake Street also maintained a Buy rating on the stock with a $10.00 price target.

See the top stocks recommended by analysts >>

Based on Accuray’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $111 million and GAAP net loss of $11.09 million. In comparison, last year the company earned revenue of $94.98 million and had a GAAP net loss of $152K.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes cyberKnife and tomo therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.

Read More on ARAY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More